What happened with BDTX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Black Diamond Therapeutics develops cancer medicines for patients whose tumors carry specific genetic mutations. Its work centers on silevertinib, a drug designed to reach the brain and inhibit EGFR, a protein involved in cancer growth. It is testing the drug in a Phase 2 trial for EGFR-mutant non-small cell lung cancer and in an investigator-sponsored trial for glioblastoma, a brain cancer.
The company has no drugs approved for sale and earns no product-sales revenue. Revenue to date has come entirely from licensing intellectual property. Servier Pharmaceuticals paid upfront for worldwide rights to BDTX-4933 and now leads that drug’s development and commercialization. Black Diamond can receive further payments when specified development and sales milestones are met, plus royalties if the drug generates sales; those payments are not guaranteed.
The business depends heavily on silevertinib’s development and on Servier’s progress with BDTX-4933. Selling its own medicines would require successful trials and regulatory approval. It has funded operations mainly by selling shares and expects to need substantial additional funding to continue development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Black Diamond Therapeutics' prospects hinge on silevertinib's clinical success and on Servier advancing and selling licensed BDTX-4933, which could bring milestone payments and royalties.
BlossomHill Therapeutics' BH-30643 competes with Black Diamond's silevertinib for EGFR-mutant lung cancer, including patients whose cancer resists existing EGFR drugs. BlossomHill develops cancer medicines rather than selling approved products; BH-30643's clinical results in resistant disease are the relevant comparison.
ArriVent BioPharma's firmonertinib competes with Black Diamond's silevertinib to treat EGFR mutation-positive lung cancer. ArriVent has no approved products or revenue yet; watch firmonertinib's safety, effectiveness and progress toward approval, the factors that could narrow silevertinib's opportunity.
Oric Pharmaceuticals' enozertinib competes with Black Diamond's EGFR drug program for lung cancers carrying exon 20 or atypical EGFR mutations. ORIC's medicines are not yet approved for sale, so enozertinib's clinical results in those patient groups matter more to this comparison than commercial revenue.
Cullinan Therapeutics' zipalertinib targets lung-cancer patients who overlap with Black Diamond's silevertinib, although Cullinan also develops autoimmune treatments. Taiho will sell zipalertinib, with Cullinan entitled to half of potential U.S. pre-tax profits; zipalertinib's progress in EGFR exon 20 insertion lung cancer is the part most relevant to Black Diamond.
C4 Therapeutics offers a competing approach to Black Diamond's silevertinib: its CFT8919 is designed to break down mutant EGFR protein rather than inhibit it in lung cancer. Watch CFT8919's clinical development in patients with the EGFR L858R mutation, which Betta Pharma conducts in Greater China.
AstraZeneca's Tagrisso sets the treatment benchmark for Black Diamond's silevertinib and the resistance setting it seeks to address in EGFR-mutant lung cancer. AstraZeneca already earns revenue from Tagrisso sales; its use as first-line treatment for classical EGFR mutations and what happens when patients develop resistance are the relevant reference points.
Johnson & Johnson already sells approved EGFR-directed lung-cancer treatments that compete for patients Black Diamond's silevertinib seeks to treat. Watch its Rybrevant combinations: with lazertinib in first-line classical EGFR-mutant disease, and with platinum-based chemotherapy after osimertinib.
AstraZeneca PLC earningsAZN
AstraZeneca’s report will show how firmly Tagrisso sells as a treatment benchmark in EGFR-mutant lung cancer, giving context for the resistance-treatment opportunity Black Diamond is pursuing with silevertinib.
Look at Tagrisso sales and, if AstraZeneca discusses them, its use as a first-line treatment and the problem of resistance. Strong sales would confirm an established treatment benchmark, not show that Black Diamond’s drug can outperform it. If the report also indicates that resistance remains a challenge, that would make room for a different treatment approach more plausible. Weaker sales would make the benchmark’s commercial footing less clear, but would not prove Black Diamond’s candidate works. The takeaway is how established the current treatment is and whether resistance still leaves a gap for a new drug to address.
Black Diamond Therapeutics, Inc. earningsThis company
Black Diamond has no approved drugs, so its report will show whether cash and research spending can still support clinical development of its lead candidate, silevertinib.
Read the cash balance alongside cash used in operations; if the report breaks out research spending by program, check silevertinib too. Cash use consistent with the company’s stated runway into the second half of 2028, alongside continued work on the lead program, would suggest development remains funded for now. Faster cash depletion or a marked pullback in program spending would point to a shorter funding window or more constrained development. Black Diamond has no product sales, and license income depends on contract payment conditions, so a quarter’s revenue alone does not show that drug sales have begun. The figures ultimately show how much room the company has to advance its lead program.
ArriVent BioPharma, Inc. earningsAVBP
ArriVent BioPharma’s report will show firmonertinib’s clinical evidence and development progress, which could determine whether it becomes another option competing with Black Diamond’s silevertinib for EGFR-mutant lung cancer patients.
Watch firmonertinib’s clinical activity in the relevant patients, its safety, and how development progresses. Convincing benefit with manageable side effects and continued progress would make ArriVent a stronger option for those patients and narrow the opening for Black Diamond. Limited benefit, safety problems, or delays would ease that competitive pressure, but would not show that silevertinib works. The conclusion is how strong this competing clinical program is and how much competition Black Diamond still faces.
